Passage BIO, Inc.
For the period ended Dec 31, 2025. Filed Mar 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 3, 2026
PASG$3.43-13.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
| | | | | | | |
|---|---|---|---|---|---|---|
| · · December 31, | ||||||
| (in thousands, except share and per share data) · · 2025 · · 2024 | ||||||
| Assets · · · · | ||||||
| Current assets: · · · · | ||||||
| Cash and cash equivalents | | $46,303 | | $37,573 | ||
| Marketable securities | | | — | | | 39,183 |
| Prepaid expenses and other current assets | | 629 | | 838 | ||
| Prepaid research and development | | 830 | | 1,221 | ||
| Total current assets | | 47,762 | | 78,815 | ||
| Property and equipment, net | | 4,107 | | 9,331 | ||
| Right of use assets - operating leases | | | 10,168 | | 13,803 | |
| Other assets | | 244 | | 463 | ||
| Total assets | | $62,281 | | $102,412 | ||
| Liabilities and stockholders’ equity | | | | | ||
| Current liabilities: | | | | | ||
| Accounts payable | | $1,113 | | $742 | ||
| Accrued expenses and other current liabilities | | 4,653 | | 6,707 | ||
| Non-refundable sublicense and transition services payments | | | 13,750 | | | 8,226 |
| Operating lease liabilities | | | 3,567 | | 3,688 | |
| Total current liabilities | | 23,083 | | 19,363 | ||
| Operating lease liabilities - noncurrent | | 20,443 | | 21,788 | ||
| Total liabilities | | 43,526 | | 41,151 | ||
| | | | | | | |
| Commitments and contingencies (note 11) | | | | | ||
| | | | | | | |
| Stockholders’ equity: | | | | | ||
| Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding at both December 31, 2025 and December 31, 2024 | | | — | | | — |
| Common stock, $0.0001 par value: 300,000,000 shares authorized; 3,182,810 shares issued and outstanding at December 31, 2025 and 3,161,503 shares issued and outstanding at December 31, 2024 | | — | | — | ||
| Additional paid‑in capital | | 723,512 | | 720,488 | ||
| Accumulated other comprehensive income (loss) | | | — | | | 8 |
| Accumulated deficit | | (704,757) | | (659,235) | ||
| Total stockholders’ equity | | 18,755 | | 61,261 | ||
| Total liabilities and stockholders’ equity | | $62,281 | | $102,412 | ||
Passage Bio, Inc.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.